Molecular Neurobiology, University of Groningen, Haren, The Netherlands.
Neuropharmacology. 2010 Sep-Oct;59(4-5):334-42. doi: 10.1016/j.neuropharm.2010.07.013. Epub 2010 Jul 23.
Amyloid-beta (Abeta) is toxic to neurons and such toxicity is - at least in part - mediated via the NMDA receptor. Calpain, a calcium dependent cystein protease, is part of the NMDA receptor-induced neurodegeneration pathway, and we previously reported that inhibition of calpain prevents excitotoxic lesions of the cholinergic nucleus basalis magnocellularis of Meynert. The present study reveals that inhibition of calpain is also neuroprotective in an in vivo model of Abeta oligomer-induced neurodegeneration in rats. Abeta-induced lesions of the nucleus basalis induced a significant decrease in the number of cholinergic neurons and their projecting fibers, as determined by analysis of choline-acetyltransferase in the nucleus basalis magnocellularis and cortical mantle of the lesioned animals. Treatment with the calpain inhibitor A-705253 significantly attenuated cholinergic neurodegeneration in a dose-dependent manner. Calpain inhibition also significantly diminished the accompanying neuroinflammatory response, as determined by immunohistochemical analysis of microglia activation. Administration of beta-amyloid markedly impaired performance in the novel object recognition test. Treatment with the calpain inhibitor, A-705253, dose-dependently prevented this behavioral deficit. In order to determine whether pre-treatment with the calpain inhibitor is necessary to exhibit its full protective effect on neurons we induced Abeta toxicity in primary neuronal cultures and administered A-705253 at various time points before and after Abeta oligomer application. Although the protective effect was higher when A-705253 was applied before induction of Abeta toxicity, calpain inhibition was still beneficial when applied up to 1h post-treatment. We conclude that inhibition of calpains may represent a valuable strategy for the prevention of Abeta oligomer-induced neuronal decline and associated cognitive deterioration.
淀粉样蛋白-β(Abeta)对神经元有毒性,这种毒性至少部分是通过 NMDA 受体介导的。钙蛋白酶是一种依赖钙的半胱氨酸蛋白酶,是 NMDA 受体诱导的神经退行性变途径的一部分,我们之前的研究报告表明,钙蛋白酶抑制可防止梅内尔特胆碱能核基底核的兴奋性损伤。本研究表明,钙蛋白酶抑制在 Abeta 寡聚体诱导的大鼠体内模型中也具有神经保护作用。Abeta 诱导的基底核损伤导致胆碱能神经元及其投射纤维的数量明显减少,这可以通过分析损伤动物基底核大细胞和皮质层的胆碱乙酰转移酶来确定。用钙蛋白酶抑制剂 A-705253 进行治疗以剂量依赖性方式显著减轻胆碱能神经退行性变。钙蛋白酶抑制还显著减弱了伴随的神经炎症反应,这可以通过小胶质细胞激活的免疫组织化学分析来确定。给予β-淀粉样蛋白会明显损害新物体识别测试中的表现。用钙蛋白酶抑制剂 A-705253 进行治疗可剂量依赖性地防止这种行为缺陷。为了确定是否需要预先用钙蛋白酶抑制剂预处理才能表现出其对神经元的全部保护作用,我们在原代神经元培养物中诱导 Abeta 毒性,并在 Abeta 寡聚体应用之前和之后的不同时间点给予 A-705253。尽管在诱导 Abeta 毒性之前应用 A-705253 时保护作用更高,但在治疗后 1 小时内应用钙蛋白酶抑制剂仍有益。我们得出结论,钙蛋白酶抑制可能是预防 Abeta 寡聚体诱导的神经元下降和相关认知恶化的有价值策略。